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Analyses of bumetanide's dose-response relationship have been complicated by the hysteresis 
observed between the drug's urinary excretion rate and its sodium excretion. This apparent time 
lag reflects the disequilibrium between the urine concentration and effect compartment (biophase) 
which occurs during the early distribution phase. In the present article, an expanded pharmaco- 
dynamic model has been introduced in which the hypothetical effect compartment is linked, by 
a first-order process (Ku~), to the urine compartment. Drug dissipation from the effect compartment 
occurs by means of the first-order rate constant, K~o. This representation accommodates 
bumetanide's luminal site of action in the kidney tubule as well as the drug's temporal component. 
Application of this model to the bumetanide-indomethacin interaction in dogs is examined. 
KEY WORDS: bumetanide; indomethacin; effect-compartment model; dose-response 
relationship. 
I N T R O D U C T I O N  
B u m e t a n i d e  is a new diure t ic  which inhibi ts  so lu te  r e a b s o r p t i o n  in the  
th ick ascending  l imb of the  loop  of H e n l e  and to a lesser  ex ten t  in the  
p r o x i m a l  tubu le  (1-4) .  The re ,  the  d rug  exer t s  its na t r iu re t i c  and  d iure t ic  
effect f rom the  lumina l  surface of the  k idney  n e p h r o n  (3). In  addi t ion ,  
ind i rec t  s tudies  wi th  i ndome thac in  have  sugges ted  tha t  the  p h a r m a c o -  
dynamic  r e sponse  to  b u m e t a n i d e  m a y  be  p r o s t a g l a n d i n - m e d i a t e d  (5-9) .  
This work was supported in part by a Biomedical Research Support Grant from the College 
of Pharmacy and a Faculty Research Rackham Grant, The University of Michigan. During 
the course of this work, H. S. H. Lau received support as a National Institutes of Health 
Predoctoral Scholar on NIH Training Grant GM 07767-04. 
~College of Pharmacy, The University of Michigan, Ann Arbor, Michigan 48109. 
2Author to whom correspondence should be addressed. 
3Present address: Department of Pharmaceutics, College of Pharmacy, The University of 
Utah, Salt Lake City, Utah 84112. 
355 
0090-466X/83/0800-0355503,00/0 (~) 1983 Plenum Publishing Corporation 
356 Smith, Lau, and Fox 
Previous studies (5-8,10-13) have been vague and conflicting in 
attempting to define the determinants of bumetanide response. This is not 
surprising since these investigators did not measure the concentrations of 
bumetanide in a sampling compartment reflective of the drug's site of action. 
Nevertheless, we have subsequently demonstrated (a) that bumetanide 
urinary excretion rate was a better indicator of natriuresis than was plasma 
concentration (14), and (b) that indomethacin diminishes the pharmaco- 
dynamic response to bumetanide by a mechanism other than prostaglandin- 
mediated changes in renal hemodynamics (9). However, in the one study 
(14) we commented that data analyses were complicated by the hysteresis 
or time lag observed between the urinary excretion rate of bumetanide and 
sodium excretion during the early time periods. A similar hysteresis was 
also observed when bumetanide was administered concomitantly with 
indomethacin (9) and reflects the disequilibrium between the urine con- 
centration and effect compartment (biophase) which occurs during the early 
distribution phase. 
In the present article, we have expanded upon a previously proposed 
pharmacodynamic model by Sheiner and coworkers (15-17). However, the 
hypothetical effect compartment is now connected to the urine compart- 
ment, as opposed to the plasma compartment. The revised model which 
we propose should be valuable in elucidating the sensitivity as well as the 
temporal components of bumetanide response. More importantly, the pro- 
posed model affords a new method for interpreting the data of luminally 
active drugs which exhibit a hysteresis between the urine and effect compart- 
ments. The application of this model to the bumetanide-indomethacin 
interaction in dogs is examined. 
EXPERIMENTAL PROCEDURE 
Materials and Methods 
Details of the experimental protocol, drug administration schedules, 
and analytical methodologies have been previously reported (9). We sum- 
marize briefly. Four male, mongrel, conditioned, unanesthetized dogs 
weighing 22.0-29.0 kg received 0.250 mg/kg of intravenous bumetanide 
before (treatment I) and after (treatment II) indomethacin pretreatment. 
Lactated Ringer's solution was administered by vein throughout the entire 
study period for both treatments I and II at a flow rate of 2 ml/min to 
avoid fluid and electrolyte depletion. Serial plasma and urine samples 
containing bumetanide as well as indomethacin plasma concentrations were 
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determined using a high-performance liquid chromatographic (HPLC) tech- 
nique. Urinary sodium was measured by flame photometry. 
Pharmacodynamic Model  
Sheiner and coworkers (15-17) have recently proposed a hypothetical 
effect-compartment model which characterizes the temporal aspects of 
pharmacodynamics as well as the time-independent sensitivity component. 
The effect compartment is modeled as an additional compartment which is 
linked to the central compartment by a first-order process. However, the 
exponential term associated with the effect compartment does not enter 
the pharmacokinetic solution since the loss of actual drug mass from the 
central compartment is negligible. In the present model (Fig. 1), we have 
expanded this concept by linking the hypothetical effect compartment to 
the urine compartment with the first-order rate constant, K,e. Drug dissipa- 
tion from the effect compartment occurs by means of the first-order rate 
constant, Keo, which allows one to precisely characterize the temporal 
aspects of equilibrium between urinary excretion rate and effect. 
Drug 
Input 
: / /  
t . . . . . . . . . .  J 
Ae 
. . . . . . . . . . .  J 
Ke0 
Fig. 1. Proposed pharmacodynamic model, viewed as an n-compartment mammillary 
representation, where the effect compartment is linked by a first-order process to the 
urine compartment. See Appendix for explanation of symbols. 
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Equations (1) and (2) describe the change in amount of drug in the 
effect compartment  with time for the intravenous infusion of a drug into 
the central compartment  when fitted to a bi- and triexponential phar- 
macokinetic model, respectively: 4 
dAe re. t, ~ wo[(ebXl-1)(K21-A1) e -xlt (ebX2-1)(K21-A2) e -x~t 
~ X u e l X  1 u ~x  . . . . .  -t 
dt [ hl(h2-A1)(Keo-hl)  A2(A1-A2)(Keo-A2) 
(ebK'~176176 (1) 
+ K,o(Xl-Keo)(A2-Keo) I 
dA~ _ KueKluK ~ - 1)(K21 - h 0(K31 - A1) e -aJ  
d t -  L ~(A~~~Z-A~ 
(e bx2- 1)(Kzl -- AE)(K31-A2) e - ~ '  -+ 
X2(X 1 -- A2)(A 3 -- A2)(Keo -- A2) 
(e ha3 -1 ) (Kz l -  A3)(K31- h3) e -~3' -+ 
A3(A1 - ;~3) (A2 - A3)(Keo - Z3) 
( e  b K ' o  - 1)(K21-geo)(g31-geo) e - K ' o t ]  
+ j 
In Eqs. (1) and (2), there are two unknown parameters, K,~ and K~o. 
All other  pharmacokinetic parameters were previously introduced (9). K,e 
was arbitrarily assigned a value of 0.001 rain -~ in the subsequent analyses 
for two reasons. First, since the transfer of mass to the effect compartment 
is negligible, the rate constant connecting the urine compartment to the 
effect compartment  is assumed to be very small relative to the magnitude 
of the smallest rate constant of the pharmacokinetic model. Hence, under 
this assumption, the exact magnitude of K, ,  is inconsequential (15). Second, 
since we are treating the data on a comparative basis, the exact value of 
K,e is not important as long as it is consistent between treatments I and II. 
Substitution of dA~/dt from Eqs. (1) and (2), depending upon the 
pharmacokinetic model utilized, was then made into the sigmoid Emax model, 
as shown below (see Appendix for explanation of symbols): 
Emax 
-1 ~-E0 (3) E - [ (  Aeso ~ +1 
I I \ dAe/ dt,I 
Equation (3) defines the relationship between the observed pharmacological 
effect (E)  and the predicted rate of change of drug in the effect compartment 
(dA~/dt). Using the sodium excretion rate (observed effect) of bumetanide 
with time as input, the unknown parameters (K~o, E . . . .  Ae50, Eo, 3') were 
4See Appendix for the derivation of Eqs. (1) and (2) and for an explanation of symbols. 
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estimated for each dog by a nonlinear least-squares regression program (J. 
L. Fox) using the Amdah1470v/6 digital computer. The regression program 
employs a Levenberg-Marquardt minimization technique and is essentially 
an adaptation of an algorithm for systems of nonlinear equations (18, 19) 
to the present case, where the system is overdetermined and a sum of 
squares minimization is sought. This algorithm combines the rapid conver- 
gence properties of a Gauss-Newton procedure when the solution is near, 
with the slow but more likely convergence of a steepest descent procedure 
when far from the solution. A special matrix updating procedure (20) 
permits the Jacobian matrix to be economically updated on each iteration 
with no additional function evaluations required. Statistical analyses of 
the calculations were identical with those produced by Metzler's program 
(21). 
Six data sets were fitted to a pharmacodynamic model incorporating 
a biexponential pharmacokinetic equation, and two data sets were fitted to 
a model incorporating a triexponential pharmacokinetic equation. All phar- 
macodynamic and previously fitted pharmacokinetic (9) models utilized a 
weighting factor of unity. Other pharmacodynamic models were tested 
(Emax and log-linear models), but the data did not fit them as well, as 
determined by the values for R 2 and CORR. Furthermore, Eq. (3) allows 
for a sigmoidal shape of the response curve that is not allowed by the simple 
Emax model, and it is applicable outside the 20-80 % effect range to which 
the log-linear method is limited. 
RESULTS 
The pharmacodynamic parameter estimates are displayed in Table I. 
There was no significant difference (as determined by a paired t test) in 
Keo between treatments I and II, and the mean equilibrium half-lives 
(0.693/K~o) were 36.5 and 41.8 min, respectively. In addition, the con- 
fidence in the accuracy of K~o is quite high since the intraanimal coefficients 
of variation (CVs) for this parameter were less than 7%. On the other 
hand, little confidence can be placed in the values of the other estimated 
parameters (Emax, Ae5o, Eo, y) due to the large variability surrounding 
them (CVs greater than 100% in many cases). This probably reflects the 
uncertainty in estimating five unknown parameters in each animal with only 
six data points, as well as the uncertainty in characterizing the maximal 
response to drug in the effect compartment. Despite this handicap, these 
parameters were useful in the interpolation, as opposed to extrapolation, 
of the predicted pharmacodynamic effect. Figure 2 displays the ability of 
the model to accurately predict, as determined by the coefficient of determi- 
nation, the sodium excretion rate of bumetanide using pooled data from 
























































































































































































































































































































































































































































































































































































































































































































































































































































0,2 0,4 0.6 0.8 1,0 1.2 1.4 1,6 1,8 2,0 
OBSERVED SODIUM EXCRETION RATE (MEQ/MIN) 
Fig. 2. Predicted vs observed pharmacodynamic effect (sodium 
excretion rate) using pooled data of bumetanide alone (0) and 
bumetanide after indomethacin pretreatment (O). The predic- 
ted effect was determined with Eq. (3). 
Figure 3 demonstrates that a time lag exists between the bumetanide 
urinary excretion rate and sodium excretion during the early time periods 
(first 40 min). Although the excretion rate of bumetanide is greatest at 
10 min, the peak effect occurs approximately 30 rain after drug dosing. 
However,  after about 40 min the curve for sodium excretion rate begins to 
parallel that of bumetanide excretion rate. This time lag was evident during 
indomethacin pretreatment (9) as well as during the concomitant administra- 
tion of bumetanide and probenecid (14). 
Figure 4 demonstrates that the time course of dAe/dt, in contrast to 
bumetanide urinary excretion rate, follows a pattern similar to that of 
sodium excretion rate over the entire dose-response curve. This finding 
supports the premise that bumetanide hysteresis is a consequence of dis- 
equilibrium between drug in the urine and effect compartments during 
bumetanide's early distribution phase. It is also observed that the rate of 
change of drug in the effect compartment does not differ between treatments 
I and II. Nevertheless, indomethacin pretreatment resulted in a dramatic 
reduction of bumetanide-induced sodium excretion (121 • 17 for treatment 
I vs 62 .4+21.3  m E q / 4  hr for treatment II; p < 0 . 0 0 5 ;  ref. 9). The effect 
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Fig. 3. Sodium excretion rate vs midpoint t ime plot ( O - - - - O )  and urinary excretion 
rate vs midpoint  t ime plot ( * - - - * )  of bumetanide  alone. Data  are expressed as the  












of indomethacin on the dose-response curves of bumetanide is further 
illustrated in Fig. 5. Bumetanide response, in the presence of indo- 
methacin, was significantly reduced during the first 40-60 min following 
bumetanide dosing (two highest values for dAe/dt), even though the rates 
of change of bumetanide in the effect compartment were equivalent between 
treatments. 
DISCUSSION 
The determinants of bumetanide response have been poorly character- 
ized in previous studies (5-8,10-13) due to the inability of these investigators 
to measure bumetanide concentrations in the plasma and urine. Further- 
more. standard pharmacodynamic models (22) do not take into account 
any lag of effect behind changes in the plasma or urine concentrations 
during periods of disequilibrium. Therefore, an expanded pharmacodynamic 
model has been introduced in which the hypothetical effect compartment 
is linked, by a first-order process, to the urine compartment. This representa- 
tion accommodates bumetanide's luminal site of action in the kidney tubule 
as well as the drug's temporal component. 
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TIME (MIN) 
Fig. 4. Predicted rate of change of drug in the effect 
compartment vs midpoint time plots of bumetanide alone 
(O 0 )  and bumetanide after indomethacin pretreat- 
ment (O---O).  Data are expressed as the mean•  
(n =4). 
Two mechanisms are consistent with the attenuation of bumetanide's 
natriuretic and diuretic effects by indomethacin. These include the inhibition 
of prostaglandin synthesis by indomethacin (pharmacodynamic interaction) 
as well as a possible competition between bumetanide and indomethacin 
for active tubular secretion into the kidney lumen (pharmacokinetic interac- 
tion). The present analyses corroborate with those of our previous study 
(9) and further support the tenet that indomethacin diminishes the phar- 
macodynamic response to bumetanide via the inhibition of prostaglandin 
synthesis. 
The proposed pharmacodynamic model also clarifies the mechanism 
for the apparent time lag between bumetanide's effect and the drug's 
concentration. Even though the absolute values of the pharmacodynamic 
parameters (Ema• Aeso, Eo, 3') were not well characterized for reasons 
previously discussed, the most important parameter, K~o, was very well 
characterized. The ability to determine this parameter alone is significant 
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0,2 0,4 0,6 1,0 
CHANGE IN AMOUNT OF DRUG IN THE EFFECT 
COMPARTMENT WITH TIME (UG/MIN) 
I 
0,i 2,0 
Fig. 5. Observed sodium excretion rate vs predicted rate 
of change of drug in the effect compartment plots of 
bumetanide alone ( O ~ )  and bumetanide after 
indomethacin pretreatment (O-- -O) .  Data are 
expressed as the mean • SEM (n = 4). 
for several reasons. First, it quantifies the equilibrium half-life between 
drug in the urine (for the proposed model) and drug in the biophase. Second, 
it helps to clarify some of the discrepancies observed in attempting to 
elucidate the determinants of bumetanide's response. And third, this dis- 
equilibrium concept is of import when designing future experiments in 
which bumetanide effect is being correlated with the drug's urinary 
excretion. 
In general, the diuretic must reside in the body for a minimum of 3.32 
equilibration half-lives in order to achieve 90 % equilibration between the 
urine and effect compartments. Only when distribution equilibrium has 
occurred will the urinary excretion rate of bumetanide correlate with the 
drug's effect at all times (assuming no pharmacodynamic interaction). We 
are currently performing steady-state experiments so that the dose-response 
relationship of bumetanide can be defined in the absence of complicating 
kinetic factors. Furthermore, and most importantly, the proposed phar- 
macodynamic model introduces a novel method for interpreting the data 
of any luminally active drug which exhibits a hysteresis similar to that of 
bumetanide. 
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APPENDIX 
Solving the Pharmacodynamic Model (Figure 1) 
The Laplace transform for the amount of drug in the effect compart- 
ment is given by the product of the input and disposition functions: 
a,# = (ins)(ds, e) (4) 
The input function for an intravenous infusion which begins at time zero is 
ins = K~ - e-bS)/S ( 5 )  
The disposition function for the effect compartment is 
where 
Kue(ds, u) 
ds, e - (6) 
(s+Keo) 
Klu(ds, 1) 
ds, u (7) 
S 
and 
ds, 1 = 
(s+g21)(s+K31) 
(s + ~.,)(s + a2)(s + a3) 
(8) 
Substitution of Eqs. (5)-(8) into Eq. (4) results in Eq. (9): 
KuegluK~ e-bS)( s + g2a)( s + K31) 
as.e- S2(S+ )tl)(S+ h2)(S_I_A3)(S+ Keo) 
(9) 
'The anti-Laplace of Eq. (9) is 
r bK21K31 
- K  K K ~  Ae - -  u e  1 u - -  - { "  
LAIA2AsK~o 
(1-ebxl)(K21-A1)(K31-A1) e -~1' 
"~21 (/~2 --  ~ 1) (/~-3 --  a 1 ) ( g e o  - ~1)  
(1 - ebA=)(K21 - a2 )  (K31 - a2) e -a:~ 
a 2(a~-a : ) (a~-a~)(K~o-  a:) 
(1 - eb*3)(K21 -- A3)(KB1 - '~3) e -*3~ 
'~23 (~'1 --  ~ 3 ) ( ~ 2  - - /~3) (Keo  - ~3)  
-t (1 - ebK~~ -Keo) e-K'~ 1 
( l o )  
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The derivative of Eq. (10) with respect to time results in the following: 
dAe_ K bA 1 --A t Ko~(e. -1)(K21-A0(K31-A1) e 
- -  u e K l  u . . . . . . .  
dt L AI(A2-A1)(A3-A1)(Keo-A1) 
(e ha2- 1) (K21 - A2)(K31 --/~2) e-a2t -+ 
A2(A1 -- a2)(X3- A2)(Keo - a2) 
(eba3-- 1)(/(21 -- A3)(K31 - a3) e-a3' -+ 
X3(/~ 1 -/~ 3) (/~2 - X3)(Keo - a3) 
-[ (ebKe~176176 e-Ke~ (11) 
Keo(A 1 -Keo)(A2-Keo)()t3-Keo ) I 
Equation (11) is identical to Eq. (2) in the text, which describes the change 
in amount of drug in the effect compartment with time (dAe/dt), for the 
intravenous infusion of a drug that is fitted to a triexponential phar- 
macokinetic model. For a drug that is fitted to a biexponential phar- 
macokinetic model, K31 = h3, SO that 
dAe K K K~ (eba~-l)(K21-A1) e-X~t 
= ue  l u  . . . . .  + 
dt k hl(a2-~.l)(Keo--hl) 
(ebK, o--1)(K21--Keo)e-K,o'.] 
+ Keo(al-Keo)(a2-Keo) .J 
Equation (12) is identical to Eq. (1) in the text. 















amount of drug in central compartment 
amount of drug in peripheral compartment 2 
amount of drug in peripheral compartment 3 
amount of drug in effect compartment 
amount of drug in peripheral compartment n, where n is 
equal to an integer greater than 3 
amount of drug in urine compartment 
change in amount of drug in the effect compartment with 
time producing 50% of Ema x 
length of time for constant-rate intravenous infusion 
change in amount of drug in the effect compartment with time 
effect 
estimated baseline effect 
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m a x  
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K o 





A~, A2, A3 
maximum effect attributable to the drug 
parameter influencing the slope of the dose-effect curve 
zero-order infusion rate 
first-order rate constant for drug transfer from the central to 
urine compartment 
First-order rate constant for drug dissipation from the effect 
compartment 
First-order intercompartmental transfer rate constants, where 
i = 1 , 2  . . . . .  j = l , 2  . . . . .  i # j  
First-order rate constant for nonrenal elimination of drug 
from the central compartment 
First-order rate constant for drug transfer from the urine to 
effect compartment 
hybrid disposition rate constants such that A 1 is the smallest 
exponent of the )d's obtained from the polyexponential 
equation 
time 
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